Scinai Immunotherapeutics Faces Nasdaq Compliance Challenge While Pursuing Innovative Therapies

Scinai Immunotherapeutics Faces Compliance Challenge with Nasdaq; Focus on Innovative Therapies Continues

On March 12, 2026, Scinai Immunotherapeutics Ltd. receives a notification from the Nasdaq Listing Qualifications Department indicating non-compliance with the minimum bid price requirement. The company's American Depositary Shares (ADSs) have traded below the $1.00 mark for 30 consecutive business days. While this notification does not immediately threaten the listing or trading of its ADSs on the Nasdaq Capital Market, it serves as a crucial alert that the company must address. Scinai is granted a compliance period of 180 calendar days, concluding on September 8, 2026, to rectify this situation. This window provides Scinai with an opportunity to elevate its ADS closing bid price to at least $1.00 for a minimum of ten consecutive business days which is essential for regaining compliance.

Despite these challenges, Scinai Immunotherapeutics is committed to its mission in the biopharmaceutical sector, focusing on innovative immunology therapies. The company’s therapeutic pipeline features candidates licensed from esteemed institutions like the Max Planck Society and PinCell S.r.l., highlighting its dedication to scientific advancement. As a player in the highly competitive field of immunotherapy, Scinai’s successful development and commercialization of novel therapies are critical not only for its potential market position but also for addressing unmet medical needs.

Simultaneously, Scinai operates Scinai Biopharma Services Ltd., offering contract development and manufacturing solutions for biotechnology and pharmaceutical firms. This subsidiary strengthens the company’s growth strategy and builds its reputation in the biopharmaceutical industry by providing key services that enhance the drug development process. The broader implications of Scinai's initiatives emphasize its capacity to navigate current hurdles while expanding its influence through effective partnerships and innovative service offerings.

In light of the press release, Scinai Immunotherapeutics is actively monitoring the performance of its ADSs and exploring various avenues to ensure compliance with Nasdaq's listing standards. The company underscores that recovery strategies may be influenced by market conditions, which could affect the trading price of its ADSs. For further details on Scinai's innovative approaches and corporate updates, stakeholders are encouraged to visit the company’s website at www.scinai.com.